Literature DB >> 16534789

Survivin: an inhibitor of apoptosis in pediatric cancer.

Jason R Fangusaro1, Hugo Caldas, Yuying Jiang, Rachel A Altura.   

Abstract

Survivin is an inhibitor of apoptosis protein (IAP) expressed in a large number of adult malignancies. Its expression levels correlate with more aggressive disease and poor clinical outcome in many of these tumors. As its expression is restricted in normal adult differentiated tissues, it has become of great interest as both a tumor prognostic marker and as a potential biologic target for future anti-cancer therapies. Survivin expression and Survivin-based therapies have been examined in many of the more common pediatric malignancies. We present an overview of Survivin function and current research exploring its biologic and therapeutic roles in pediatric tumors. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534789     DOI: 10.1002/pbc.20805

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  12 in total

1.  Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein.

Authors:  Y Shao; Y Liu; C Shao; J Hu; X Li; F Li; L Zhang; D Zhao; L Sun; X Zhao; D J Kopecko; D V Kalvakolanu; Y Li; D Q Xu
Journal:  Cancer Gene Ther       Date:  2010-08-13       Impact factor: 5.987

2.  Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.

Authors:  D J Morrison; L E Hogan; G Condos; T Bhatla; N Germino; N P Moskowitz; L Lee; D Bhojwani; T M Horton; I Belitskaya-Levy; L M Greenberger; I D Horak; S A Grupp; D T Teachey; E A Raetz; W L Carroll
Journal:  Leukemia       Date:  2011-08-16       Impact factor: 11.528

3.  The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.

Authors:  Augusto Faria Andrade; Kleiton Silva Borges; Veridiana Kiill Suazo; Lenisa Geron; Carolina Alves Pereira Corrêa; Angel Mauricio Castro-Gamero; Elton José Rosas de Vasconcelos; Ricardo Santos de Oliveira; Luciano Neder; José Andres Yunes; Simone Dos Santos Aguiar; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  Invest New Drugs       Date:  2016-10-26       Impact factor: 3.850

Review 4.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13

5.  Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na⁺/K⁺-ATPase α3 subunit-involved mitochondrial stress and amplification of caspase cascades.

Authors:  She-Hung Chan; Wohn-Jenn Leu; Lih-Ching Hsu; Hsun-Shuo Chang; Tsong-Long Hwang; Ih-Sheng Chen; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

6.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

7.  Overexpression of survivin initiates hematologic malignancies in vivo.

Authors:  S Small; G Keerthivasan; Z Huang; S Gurbuxani; J D Crispino
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

8.  Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia.

Authors:  Smita Dandekar; Eleny Romanos-Sirakis; Faye Pais; Teena Bhatla; Courtney Jones; Wallace Bourgeois; Stephen P Hunger; Elizabeth A Raetz; Michelle L Hermiston; Ramanuj Dasgupta; Debra J Morrison; William L Carroll
Journal:  Br J Haematol       Date:  2014-07-04       Impact factor: 6.998

9.  A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Authors:  Elizabeth A Raetz; Debra Morrison; Eleny Romanos-Sirakis; Paul Gaynon; Richard Sposto; Deepa Bhojwani; Bruce C Bostrom; Patrick Brown; Elena Eckroth; Jeannette Cassar; Jemily Malvar; Aby Buchbinder; William L Carroll
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

10.  Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy.

Authors:  Jian Gang Zhang; Carol A Kruse; Lara Driggers; Neil Hoa; Jeffrey Wisoff; Jeffrey C Allen; David Zagzag; Elizabeth W Newcomb; Martin R Jadus
Journal:  J Neurooncol       Date:  2008-02-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.